Wolf, J. M., Gubert Borges, B., Pereira Fagundes, P., de Souza, V., Brenner, A., Petek, H., Michelon dos Santos, W., Gasparetto Maccari, J., Rohsig, V., Parrini Mutlaq, M., & Nasi, L. A. (2023). Adverse drug events, comorbidities, and older age are statistically more prevalent in COVID-19 hospitalized patients treated with remdesivir than tocilizumab in a private hospital from southern Brazil. Clinical and Biomedical Research, 43(3). Recuperado de https://seer.ufrgs.br/index.php/hcpa/article/view/129384